Brief: Hepion Pharma Announces Positive Top Line Data For Low Dose Crv431 In Phase 2A 'Ambition' Clinical Trial For Treatment Of Advanced Nash
29/12/2020 21:28
Dec 29 (Reuters) - Hepion Pharmaceuticals Inc HEPA.O :
* HEPION PHARMACEUTICALS INC. - HEPION PHARMACEUTICALS
ANNOUNCES
POSITIVE TOP LINE DATA FOR LOW DOSE CRV431 IN PHASE 2A
'AMBITION' CLINICAL TRIAL FOR TREATMENT OF ADVANCED NASH
* HEPION PHARMACEUTICALS INC - CRV431 DEMONSTRATED TO BE
GENERALLY
SAFE AND WELL TOLERATED
* HEPION PHARMACEUTICALS - PHASE 2A STUDY IS CONTINUING WITH
HIGHER DOSE OF 225 MG CRV431, WITH NASH PATIENT DOSING EXPECTED
TO BE COMPLETED IN Q1-2021
Source text for Eikon: ID:nNDL4KhVR4
Further company coverage: HEPA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Hepion Pharmaceuticals
See all newsBrief: Hepion Pharmaceuticals Executes Binding Letter Of Intent With New Day Diagnostics To Commercialize Diagnostic Tests For Celiac Disease, Respiratory Multiplex, H. Pylori And Hcc
Brief: Hepion Pharma In-Licenses Diagnostic Tests from New Day Diagnostics- SEC Filing
Brief: Hepion Pharmaceuticals Announces Termination Of Merger Agreement With Pharma Two B
Brief: Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B
Brief: Pharma Two B Plans To Go Public Via Merger With Hepion Pharmaceuticals, Concurrent $11.5 Mln Private Placement